USANA Health Sciences, Inc. filings document financial results, management commentary and Regulation FD disclosures for a health and wellness products company. Form 8-K reports cover quarterly and annual results, preliminary sales information, guidance, exhibits and conference-call materials tied to the company’s operating updates.
Proxy and governance filings address director elections, board matters, executive compensation, equity awards and pay-versus-performance disclosure. Other material-event reports document leadership changes, transition agreements and compensatory arrangements, providing formal records of governance and management structure for USANA Health Sciences.
BlackRock, Inc. has filed an amended Schedule 13G reporting a passive ownership stake in USANA Health Sciences Inc. common stock. BlackRock reports beneficial ownership of 799,296 shares, representing 4.4% of USANA’s outstanding common stock as of the event date December 31, 2025. It has sole voting power over 788,094 shares and sole dispositive power over 799,296 shares, with no shared voting or dispositive power. The filing states that the shares are held in the ordinary course of business and not for the purpose of changing or influencing control of USANA. Various underlying clients have rights to dividends or sale proceeds, but no single client holds more than five percent of the outstanding common shares through BlackRock.
USANA Health Sciences, Inc. reported that it has issued a press release with preliminary net sales for the full fiscal year ended January 3, 2026. The company also provided net sales guidance for its currently expected financial results for the fiscal year ending January 2, 2027. This information is furnished under Items 2.02 and 7.01 and is attached as Exhibit 99.1. The company states that this information is being furnished rather than filed under the Exchange Act and is not incorporated by reference into Securities Act registration statements.
USANA Health Sciences, Inc. reported a leadership transition in which Jim Brown has stepped down as Chief Executive Officer and President, effective January 8, 2026. He will remain with the company in an advisory role for a period at the discretion of the Board of Directors, providing some continuity during the change.
Kevin Guest, age 63, who currently serves as Executive Chairman of the Board and previously served as Chief Executive Officer, will reassume the role of Chief Executive Officer while continuing as Chairman. The company states there is no arrangement or understanding with any other person regarding his selection, and no family or related-party relationships requiring additional disclosure. The Compensation Committee has not yet determined the compensation arrangements for Mr. Brown’s separation or for Mr. Guest’s new role as Chief Executive Officer and expects to decide these shortly, after which an amendment will be filed. The company has issued a press release describing these changes.
USANA Health Sciences Inc. insider reports small stock sale. The company’s Chief Sales Officer filed a Form 4 disclosing the sale of 873 shares of USANA common stock on 12/10/2025. The shares were sold at a price of $21 per share, using transaction code “S,” which indicates an open market or private sale.
After this transaction, the officer beneficially owns 8,387 shares of USANA common stock in direct ownership. The filing is made by a single reporting person and does not report any derivative securities activity.
USANA Health Sciences Inc. (USNA) reported an insider stock transaction by its Chief Information Officer. On 12/10/2025, the officer sold 2,673 shares of common stock in an open market transaction at a price of $20.9506 per share, coded as a sale ("S"). After this transaction, the reporting person held 0 shares of USANA common stock in direct ownership. The filing covers only non-derivative common stock, with no derivative securities reported.
USANA Health Sciences filed a notice under Rule 144 for a planned sale of restricted common stock. The filing covers 2,673 shares of common stock, with an aggregate market value of $56,000.95, to be sold through Morgan Stanley Smith Barney LLC on the NYSE. The issuer had 18,280,857 shares of common stock outstanding. The shares were acquired from the issuer as restricted stock in several transactions dated between February 6, 2025 and July 25, 2025. The seller represents that they are not aware of any material adverse, nonpublic information about the company’s current or prospective operations.
USANA Health Sciences (USNA) Form 4: A director reported an open-market sale of common stock. On 11/10/2025, the director sold 2,000 shares (transaction code S) at a price of $19.21 per share. Following this transaction, the director beneficially owns 5,986 shares, held directly.
USANA Health Sciences reported Q3 2025 net sales of $213.7 million, up 6.7% year over year, driven by the addition of the Hiya direct‑to‑consumer business ($30.8 million) and growth in “Other,” which offset declines in direct selling.
The quarter showed a net loss of $6.5 million versus earnings of $10.6 million a year ago. Management cites a sharp increase in the annualized effective tax rate to 65% and higher selling, general and administrative costs, including amortization of acquired intangibles and elevated marketing at Hiya. Gross margin was 77.2% (down 320 bps), reflecting Hiya’s lower gross margin mix and higher “Other.”
Direct selling net sales fell as active customers decreased to 388,000, with broad softness across Asia Pacific and Americas/Europe. Cash and cash equivalents were $145.3 million and there was no balance on the $75 million revolver at quarter‑end. Year to date, USANA repurchased 927,000 shares for $27.7 million, leaving $34.0 million authorized. As of October 31, 2025, shares outstanding were 18,280,857. Subsequently, the company initiated a cost alignment program with an expected $4.7 million one‑time Q4 charge.
USANA Health Sciences (USNA) director reported a sale of 1,057 shares of common stock (Code S) at $21.4799 on 11/03/2025. Following the transaction, the director beneficially owned 0 shares, held as direct ownership (D).
USANA Health Sciences (USNA) reported an insider transaction on a Form 4. A company director sold 1,750 shares of Common Stock on 10/31/2025 at a price of $19.79 per share (transaction code: S for open-market sale). After this trade, the insider directly beneficially owns 4,565 shares.